What is Allermi?
Allermi is focused on addressing the limitations of current allergy products, particularly oral medications that can lead to systemic side effects. The company's approach involves targeted delivery systems, such as nasal sprays and topical ointments, to ensure medication is applied precisely where needed. This method aims to significantly reduce overall medication absorption by the body, thereby minimizing the required dosage and mitigating the risk of adverse reactions. Allermi's innovative treatments are designed to offer a more effective and safer alternative for allergy sufferers.
How much funding has Allermi raised?
Allermi has raised a total of $4.8M across 2 funding rounds:
Other Financing Round
$1.3M
Angel/Seed
$3.5M
Other Financing Round (2022): $1.3M with participation from Lucas Venture Group
Angel/Seed (2023): $3.5M led by Nelstone Ventures and FourSight Capital Partners
Key Investors in Allermi
Nelstone Ventures
Nelstone Ventures is an investment firm specializing in sectors including enterprise software, gaming, healthcare, and consumer internet, focusing on technology-enhanced businesses.
FourSight Capital Partners
FourSight Capital Partners is a boutique family investment firm that supports overlooked entrepreneurs and managers, investing across various asset classes and deploying capital through its funds and network of ultra-high-net-worth families.
Lucas Venture Group
Lucas Venture Group is a third-generation venture capital firm investing in diverse sectors including e-commerce, AI, fintech, and medical devices, known for its strong network and collaborative approach.
What's next for Allermi?
With the recent major strategic investment, Allermi is poised for significant expansion and further development of its targeted allergy therapies. This enterprise-level funding suggests a transition from early-stage development to a scaling phase, likely focusing on clinical trials, regulatory approvals, and market penetration. The company's strategic focus on localized drug delivery positions it to capture a substantial share of the allergy treatment market, potentially disrupting traditional oral medication approaches. Future endeavors will likely involve broadening the product pipeline and establishing key partnerships to accelerate commercialization.
See full Allermi company page
